The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in Chinese patients (pts) with HER2-positive early breast cancer (EBC): Primary analysis of the phase III, randomised FDChina study

被引：0
作者：
Shao, Z. [1 ]
Huang, T. [2 ]
Fan, Z. [3 ]
Wang, Y. [4 ]
Yan, X. [5 ]
Yang, H. [6 ]
Wang, S. [7 ]
Pang, D. [8 ]
Li, H. [9 ]
Wang, H. [10 ]
Geng, C. [11 ]
Huang, L. [12 ]
Siddiqui, A. [13 ]
Wang, B. [14 ]
Xie, B. [15 ]
Sun, G. [16 ]
Restuccia, E. [17 ]
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Breast Canc, Shanghai, Peoples R China
[2] Tongji Med Coll, Dept Breast & Thyroid Surg, Wuhan, Peoples R China
[3] Jilin Univ, Dept Breast Surg, Changchun, Peoples R China
[4] Shandong Canc Hosp, Breast Canc Ctr, Jinan, Peoples R China
[5] Sichuan Univ, West China Hosp, Med Oncol, Chengdu, Peoples R China
[6] Zhejiang Canc Hosp, Breast Surg, Hangzhou, Peoples R China
[7] Peking Univ Peoples Hosp, Breast Ctr, Beijing, Peoples R China
[8] Harbin Med Univ, Dept Breast Surg, Harbin, Peoples R China
[9] Beijing Canc Hosp, Breast Canc Ctr, Beijing, Peoples R China
[10] Affiliated Hosp Qingdao Univ, Dept Breast Ctr, Qingdao, Peoples R China
[11] Fourth Hosp Hebei Med Univ, Breast Ctr, Shijiazhuang, Hebei, Peoples R China
[12] Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, Shanghai, Peoples R China
[13] Roche Prod Ltd, Prod Dev Clin Oncol, Welwyn Garden City, Herts, England
[14] Genentech Inc, Clin Pharmacol, San Francisco, CA 94080 USA
[15] Roche China Holding Co Ltd, Biostat, Shanghai, Peoples R China
[16] Roche China Holding Co Ltd, PD China, Shanghai, Peoples R China
[17] F Hoffmann La Roche Ltd, Prod Dev Oncol, Basel, Switzerland
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1MO
引用
收藏
页码：S1431 / S1431
页数：1
相关论文
共 50 条
  • [1] Anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab (PH IV) or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) for HER2-positive breast cancer (BC)
    Swain, S. M.
    Tan, A.
    Gianni, L.
    Kummel, S.
    Dang, C.
    Schneeweiss, A.
    O'Shaughnessy, J.
    Liu, H.
    Aguila, C.
    Heeson, S.
    Macharia, H.
    Restuccia, E.
    Loibl, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S419 - S420
  • [2] Patient (pt) preference for the pertuzumab-trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) in HER2-positive early breast cancer (EBC): Primary analysis of the open-label, randomised crossover PHranceSCa study
    O'Shaughnessy, J.
    Sousa, S.
    Cruz, J.
    Fallowfield, L.
    Auvinen, P.
    Pulido, C.
    Cvetanovic, A.
    Wilks, S.
    Ribeiro, L.
    Burotto, M.
    Klingbiel, D.
    Messeri, D.
    Alexandrou, A.
    Trask, P.
    Fredriksson, J.
    Machackova, Z.
    Stamatovic, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S306 - S307
  • [3] Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus chemotherapy in HER2-positive early breast cancer (EBC): Safety results from the adjuvant phase of the randomised, open-label, multicentre phase III (neo)adjuvant FeDeriCa study
    Im, S-A.
    Tan, A. R.
    Mattar, A.
    Colomer, R.
    Stroyakovskii, D.
    Nowecki, Z.
    De Laurentiis, M.
    Pierga, J-Y.
    Jung, K. H.
    Schem, C.
    Aguila, C.
    Crnjevic, T. Badovinac
    Heeson, S.
    Shivhare, M.
    Alexandrou, A.
    Restuccia, E.
    Jackisch, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S40 - S41
  • [4] Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive breast cancer: A multidisciplinary approach
    DuMond, Barbara
    Patel, Vidhi
    Gross, Anne
    Fung, Anita
    Weber, Susan
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (05) : 1214 - 1221
  • [5] A Clinical Review of Subcutaneous Trastuzumab and the Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in the Treatment of HER2-Positive Breast Cancer
    Ziegengeist, Julia L.
    Tan, Antoinette R.
    CLINICAL BREAST CANCER, 2025, 25 (02) : e124 - e132
  • [6] The PHASTER Study: Economic and Organizational Impact of Subcutaneous (SC) Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Treatment of HER2+ Breast Cancer Patients
    Elisabetta Munzone
    Alessandra Fabi
    Giuseppe Buono
    Roberta Caputo
    Emilia Montagna
    Mara Negri
    Francesco Nuzzo
    Antonella Palazzo
    Ida Paris
    Luca Conti
    Anna Baggi
    Jean Marie Franzini
    Michelino De Laurentiis
    Drugs & Therapy Perspectives, 2023, 39 : 432 - 446
  • [7] The PHASTER Study: Economic and Organizational Impact of Subcutaneous (SC) Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Treatment of HER2+Breast Cancer Patients
    Munzone, Elisabetta
    Fabi, Alessandra
    Buono, Giuseppe
    Caputo, Roberta
    Montagna, Emilia
    Negri, Mara
    Nuzzo, Francesco
    Palazzo, Antonella
    Paris, Ida
    Conti, Luca
    Baggi, Anna
    Franzini, Jean Marie
    De Laurentiis, Michelino
    DRUGS & THERAPY PERSPECTIVES, 2023, 39 (12) : 432 - 446
  • [8] Time and motion study of a subcutaneous fixed-dose combination of pertuzumab and trastuzumab for the treatment of patients with HER2-positive early breast cancer (PHaTiMa)
    Gregori, Joaquin Gavila
    Miranda, Elena Lopez
    Escriva-de-Romani, Santiago
    Rodriguez, Begona Jimenez
    Novoa, Silvia Antolin
    Morales, Luis Fernandez
    Calvo, Elena Galve
    Cortijo, Lucia Gonzalez
    Martorell, Antonia Perello
    Ruiz, Julian Lagunar
    Santiago, Santiago Gonzalez
    CANCER RESEARCH, 2022, 82 (04)
  • [9] Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study
    Bei Wang
    Rong Deng
    Stefanie Hennig
    Tanja Badovinac Crnjevic
    Monika Kaewphluk
    Matts Kågedal
    Angelica L. Quartino
    Sandhya Girish
    Chunze Li
    Whitney P. Kirschbrown
    Cancer Chemotherapy and Pharmacology, 2021, 88 : 499 - 512
  • [10] Original Research Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study
    O'Shaughnessy, Joyce
    Sousa, Susana
    Cruz, Josefina
    Fallowfield, Lesley
    Auvinen, Paivi
    Pulido, Catarina
    Cvetanovic, Ana
    Wilks, Sharon
    Ribeiro, Leonor
    Burotto, Mauricio
    Klingbiel, Dirk
    Messeri, Dimitri
    Alexandrou, Ari
    Trask, Peter
    Fredriksson, Judy
    Machackova, Zuzana
    Stamatovic, Ljiljana
    EUROPEAN JOURNAL OF CANCER, 2021, 152 : 223 - 232
12345